TY - JOUR T1 - Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - 2820 AU - Ulrich Costabel AU - Carlo Albera AU - Williamson Bradford AU - Phil Hormel AU - Talmadge King AU - Paul Noble AU - Steven Sahn AU - Dominique Valeyre AU - Roland du Bois Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/2820.abstract N2 - Introduction: RECAP is an open-label extension study evaluating long-term treatment with PFD in IPF patients who completed one of the CAPACITY (CAP) trials.Objective: Further examine the effect of PFD on lung function and survival in patients with IPF.Methods: PFD 2403 mg/d was administered orally in 3 equally divided doses. Forced vital capacity (FVC) was measured at baseline and Wks 12, 36, and 60. To facilitate comparison with CAP outcomes, analyses were based on patients newly-treated with PFD in RECAP who had baseline FVC and DLco values that met CAP entry criteria.Results: A total of 178 patients were newly-treated with PFD in RECAP and had baseline values that met CAP entry criteria. The mean change from baseline to Wk 60 in %FVC in this group was –5.8%; mean change over the corresponding period in CAP was –7.0% in the PFD group (N=345) and –9.4% in the placebo group (N=347). The percentage of patients with an FVC decline ≥10% was 16.6% in RECAP, compared with 16.8% and 24.8%, respectively, in the PFD and placebo groups in CAP. Overall survival in newly-treated patients in RECAP was similar to that of PFD patients in CAP (Figure 1). Conclusions: FVC and survival outcomes in IPF patients newly treated with PFD in RECAP were similar to those in PFD-treated patients in CAP. These data provide further evidence to support the use of PFD in patients with IPF. ER -